People: GSK's European Senior VP to Sort Out China Problems
Gisserot replaces Mark Reilly who left China shortly after Chinese authorities raided GSK offices, detaining employees and seizing documents, the Wall Street Journal reported, though Reilly is not accused of any wrongdoing.
However, the firm admitted last week some of its senior executives may have breached China law.
Speaking in a conference call with investors last Wednesday, GSK CEO Sir Andrew Witty told stakeholders the China issue is wholly “domestic investigation” and GSK were working close with the Chinese in an investigation that is currently in its early stages.
He said: “It appears that certain senior managers in the Chinese business have acted outside of our processes and our controls to both defraud the company and the Chinese healthcare system.
“To see these allegations made about people working for GSK is as we have said shameful and for me personally they are deeply disappointing.”
Gisserot is currently Senior VP for GSK Europe and is also President of Les Entreprises du Medicament (LEEM ) – the pharmaceutical industry body in France.
Due to the new role that begins September 1, Gisserot is stepping down and will be replaced in the interim by Patrick Errard, CEO of the French subsidiary of Astellas pharma.
To the US now, and Biomed Pharmaceuticals has appointed Gaston Bernstein as its new CEO.
Bernstein comes from seven years at Coram Specialty Infusion Services, the pharmacy division of Apria Healthcare, where he served as Corporate VP of Industry Relations.
He was welcomed to the role by Biomed Director, Brian Schwartz, who added: “Gaston brings a wealth of specialty pharmacy industry experience which he has gained in his 22 years of working in the healthcare industry.”
And finally this week, a quick round-up of other industry movers and shakers:
Dr. Eddie Li has joined Intarcia Therapeutics from Novo Nordisk as Vice President and Global Head of Regulatory Affairs.
Lyndon Nicholson is the new Chief Executive at WinchPharma, replacing Philip McSweeney.
Avaxia Biologics has appointed Dr. Neil Schauer as Vice President, Technical Operations, responsible for or process development, manufacturing, formulation, and quality for the entire Avaxia product candidate pipeline.
Flint Besecker has joined Kinex Pharmaceuticals as Chief Financial Officer.
